Connection

Michael Gold to Ventricular Dysfunction, Left

Back to Details
This is a "connection" page, showing publications Michael Gold has written about Ventricular Dysfunction, Left.
Michael Gold
Connection Strength
6.082
Ventricular Dysfunction, Left
  1. Redefining the Classifications of Response to Cardiac Resynchronization Therapy: Results From the REVERSE Study. JACC Clin Electrophysiol. 2021 07; 7(7):871-880.
    View in: PubMed
    Score: 0.600
  2. Optimization of Cardiac Resynchronization Therapy: Should Perioperative Hemodynamic Measurements Be Routine? JACC Clin Electrophysiol. 2019 09; 5(9):1026-1027.
    View in: PubMed
    Score: 0.541
  3. The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Heart Fail Clin. 2017 Jan; 13(1):209-223.
    View in: PubMed
    Score: 0.450
  4. The Role of Atrioventricular and Interventricular Optimization for Cardiac Resynchronization Therapy. Card Electrophysiol Clin. 2015 Dec; 7(4):765-79.
    View in: PubMed
    Score: 0.417
  5. The effect of reverse remodeling on long-term survival in mildly symptomatic patients with heart failure receiving cardiac resynchronization therapy: results of the REVERSE study. Heart Rhythm. 2015 Mar; 12(3):524-530.
    View in: PubMed
    Score: 0.388
  6. Implantable defibrillators improve survival in patients with mildly symptomatic heart failure receiving cardiac resynchronization therapy: analysis of the long-term follow-up of remodeling in systolic left ventricular dysfunction (REVERSE). Circ Arrhythm Electrophysiol. 2013 Dec; 6(6):1163-8.
    View in: PubMed
    Score: 0.360
  7. Atrial support pacing in heart failure: results from the multicenter PEGASUS CRT trial. J Cardiovasc Electrophysiol. 2012 Dec; 23(12):1317-25.
    View in: PubMed
    Score: 0.331
  8. Defibrillation thresholds in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2011 May; 22(5):569-72.
    View in: PubMed
    Score: 0.295
  9. A prospective comparison of AV delay programming methods for hemodynamic optimization during cardiac resynchronization therapy. J Cardiovasc Electrophysiol. 2007 May; 18(5):490-6.
    View in: PubMed
    Score: 0.227
  10. Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. Heart Rhythm. 2005 Apr; 2(4):376-81.
    View in: PubMed
    Score: 0.199
  11. Effects of selective autonomic blockade on T-wave alternans in humans. Circulation. 2002 Feb 19; 105(7):837-42.
    View in: PubMed
    Score: 0.161
  12. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac?Resynchronization: Results From the REVERSE Trial. JACC Heart Fail. 2017 03; 5(3):169-178.
    View in: PubMed
    Score: 0.114
  13. Performance of the subcutaneous implantable cardioverter-defibrillator in patients with a primary prevention indication with and without a reduced ejection fraction versus patients with a secondary prevention indication. Heart Rhythm. 2017 03; 14(3):367-375.
    View in: PubMed
    Score: 0.112
  14. The Role of I-123 Metaiodobenzylguanidine Imaging in Management of Patients With Heart Failure. Am J Cardiol. 2015 Oct 15; 116 Suppl 1:S1-9.
    View in: PubMed
    Score: 0.103
  15. Effects of Cardiac Resynchronization Therapy on Cardiac Remodeling and Contractile Function: Results From Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE). J Am Heart Assoc. 2015 Sep 11; 4(9):e002054.
    View in: PubMed
    Score: 0.103
  16. Reduced appropriate implantable cardioverter-defibrillator therapy after cardiac resynchronization therapy-induced left ventricular function recovery: a meta-analysis and systematic review. Eur Heart J. 2015 Nov 01; 36(41):2780-9.
    View in: PubMed
    Score: 0.102
  17. Newer Indications for ICD and CRT. Cardiol Clin. 2014 May; 32(2):181-90.
    View in: PubMed
    Score: 0.092
  18. Long-term impact of cardiac resynchronization therapy in mild heart failure: 5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Eur Heart J. 2013 Sep; 34(33):2592-9.
    View in: PubMed
    Score: 0.087
  19. Chronic kidney disease and cardiac remodelling in patients with mild heart failure: results from the REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction (REVERSE) study. Eur J Heart Fail. 2012 Dec; 14(12):1420-8.
    View in: PubMed
    Score: 0.083
  20. Effect of QRS duration and morphology on cardiac resynchronization therapy outcomes in mild heart failure: results from the Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction (REVERSE) study. Circulation. 2012 Aug 14; 126(7):822-9.
    View in: PubMed
    Score: 0.082
  21. Potential mechanisms underlying the effect of gender on response to cardiac resynchronization therapy: insights from the SMART-AV multicenter trial. Heart Rhythm. 2012 May; 9(5):736-41.
    View in: PubMed
    Score: 0.079
  22. The relationship between ventricular electrical delay and left ventricular remodelling with cardiac resynchronization therapy. Eur Heart J. 2011 Oct; 32(20):2516-24.
    View in: PubMed
    Score: 0.078
  23. Cardiac resynchronization therapy in asymptomatic or mildly symptomatic heart failure patients in relation to etiology: results from the REVERSE (REsynchronization reVErses Remodeling in Systolic Left vEntricular Dysfunction) study. J Am Coll Cardiol. 2010 Nov 23; 56(22):1826-31.
    View in: PubMed
    Score: 0.074
  24. Primary results from the SmartDelay determined AV optimization: a comparison to other AV delay methods used in cardiac resynchronization therapy (SMART-AV) trial: a randomized trial comparing empirical, echocardiography-guided, and algorithmic atrioventricular delay programming in cardiac resynchronization therapy. Circulation. 2010 Dec 21; 122(25):2660-8.
    View in: PubMed
    Score: 0.074
  25. Do Beta-blockers impact microvolt T-wave alternans testing in patients at risk for ventricular arrhythmias? A meta-analysis. J Cardiovasc Electrophysiol. 2010 Sep; 21(9):1009-14.
    View in: PubMed
    Score: 0.073
  26. Prevention of disease progression by cardiac resynchronization therapy in patients with asymptomatic or mildly symptomatic left ventricular dysfunction: insights from the European cohort of the REVERSE (Resynchronization Reverses Remodeling in Systolic Left Ventricular Dysfunction) trial. J Am Coll Cardiol. 2009 Nov 10; 54(20):1837-46.
    View in: PubMed
    Score: 0.068
  27. Role of cardiac resynchronization therapy in asymptomatic and mildly symptomatic heart failure. Curr Heart Fail Rep. 2009 Mar; 6(1):44-8.
    View in: PubMed
    Score: 0.065
  28. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol. 2008 Dec 02; 52(23):1834-1843.
    View in: PubMed
    Score: 0.064
  29. Use of traditional and biventricular implantable cardiac devices for primary and secondary prevention of sudden death. Cardiol Clin. 2008 Aug; 26(3):419-31, vi-vii.
    View in: PubMed
    Score: 0.063
  30. Baseline characteristics of patients randomized in The Resynchronization Reverses Remodeling In Systolic Left Ventricular Dysfunction (REVERSE) study. Congest Heart Fail. 2008 Mar-Apr; 14(2):66-74.
    View in: PubMed
    Score: 0.061
  31. Myocardial contractile reserve as a predictor of cardiac resynchronization therapy response. Heart Rhythm. 2006 Apr; 3(4):414-5.
    View in: PubMed
    Score: 0.053
  32. Rationale and design of a randomized controlled trial to assess the safety and efficacy of cardiac resynchronization therapy in patients with asymptomatic left ventricular dysfunction with previous symptoms or mild heart failure--the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction (REVERSE) study. Am Heart J. 2006 Feb; 151(2):288-94.
    View in: PubMed
    Score: 0.053
  33. Iatrogenic ventricular dyssynchrony: a preventable cause of heart failure with right ventricular pacing? Heart Rhythm. 2005 Mar; 2(3):252-3.
    View in: PubMed
    Score: 0.050
  34. Right ventricular outflow versus apical pacing in pacemaker patients with congestive heart failure and atrial fibrillation. J Cardiovasc Electrophysiol. 2003 Nov; 14(11):1180-6.
    View in: PubMed
    Score: 0.045
  35. T wave alternans for ventricular arrhythmia risk stratification. Minerva Cardioangiol. 2003 Feb; 51(1):15-9.
    View in: PubMed
    Score: 0.043
  36. T wave alternans for ventricular arrhythmia risk stratification. Curr Opin Cardiol. 2003 Jan; 18(1):1-5.
    View in: PubMed
    Score: 0.043
  37. Influence of QRS duration on the prognostic value of T wave alternans. J Cardiovasc Electrophysiol. 2002 Aug; 13(8):770-5.
    View in: PubMed
    Score: 0.041
  38. Clinical predictors of defibrillation thresholds with an active pectoral pulse generator lead system. Pacing Clin Electrophysiol. 2002 Apr; 25(4 Pt 1):408-13.
    View in: PubMed
    Score: 0.040
  39. T wave alternans for ventricular arrhythmia risk stratification. Curr Opin Cardiol. 2002 Jan; 17(1):1-5.
    View in: PubMed
    Score: 0.040
  40. Performance of a new steroid-eluting coronary sinus lead designed for left ventricular pacing. Pacing Clin Electrophysiol. 2000 Nov; 23(11 Pt 2):1741-3.
    View in: PubMed
    Score: 0.037
  41. Optimization of ventricular pacing: where should we implant the leads? J Am Coll Cardiol. 1999 Feb; 33(2):324-6.
    View in: PubMed
    Score: 0.032
  42. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013 Dec; 34(46):3547-56.
    View in: PubMed
    Score: 0.022
  43. Rationale and study design of the increase of vagal tone in heart failure study: INOVATE-HF. Am Heart J. 2012 Jun; 163(6):954-962.e1.
    View in: PubMed
    Score: 0.020
  44. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med. 2000 Jun 29; 342(26):1937-45.
    View in: PubMed
    Score: 0.009
  45. Gender differences in presentation, management, and cardiac event-free survival in patients with syncope. Am J Cardiol. 1997 Nov 01; 80(9):1183-7.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.